We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Amgen Gets $70M In Biosimilar Patent Suit Against Hospira

Law360, Wilmington (September 22, 2017, 10:21 PM EDT) -- A Delaware federal jury awarded Amgen Inc. $70 million in damages late Friday after finding that Hospira Inc. infringed a patent for the anemia treatment Epogen, rejecting Hospira's argument that it was protected by a safe harbor meant for companies seeking federal approval for biosimilar products.

After five hours of deliberation, the jury found that Hospira infringed Amgen's patent that covers the creation of specialized erythropoietin protein cells, or EPO, that stimulate the creation of red blood cells in anemia patients. (AP) After five hours of...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.